← Back to Search

Antiviral Agent

Group A for Chronic Obstructive Pulmonary Disease

Phase 1

Waitlist Available

Led By David Wyatt, MD

Research Sponsored by Altesa Biosciences, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, up to 3 weeks

Awards & highlights

Study Summary

This trial is testing the safety and effectiveness of vapendavir, an antiviral agent, in healthy and COPD patients. Up to 24 adults will be included; follow-up will last 14-30 days.

Eligible Conditions

Chronic Obstructive Pulmonary Disease
Respiratory Diseases
Lower Respiratory Infection
Lung Disease
Healthy Subjects

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, up to 3 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, up to 3 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pharmacokinetic Analyses

Trial Design

2Treatment groups

Experimental Treatment

Group I: Group BExperimental Treatment1 Intervention

Participants with COPD

Group II: Group AExperimental Treatment1 Intervention

Healthy Participants (HP)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Vapendavir

2015

Completed Phase 2

~460

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Altesa Biosciences, Inc.Lead Sponsor

1 Previous Clinical Trials

100 Total Patients Enrolled

David Wyatt, MDPrincipal InvestigatorVP Medical Affairs

3 Previous Clinical Trials

166 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I participate in this clinical trial?

"This medical research requires chronic obstructive pulmonary disease sufferers aged 18 to 55. The team is striving for a total of 24 participants."

Answered by AI

Has Group A obtained governmental authorization for its product?

"Our team has assigned Group A a score of 1, as this is only Phase 1 trial and there are limited findings verifying the safety and efficacy."

Answered by AI

Are any positions available in this investigation for participants?

"Contrary to expectations, clinicaltrials.gov indicates that this trial is not recruiting patients at present. It was initially advertised on May 19th 2023 and last updated on July 18th 2023. Although no longer active, there are 1,169 other studies taking part in patient enrolment right now."

Answered by AI